Dergiler / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 1

Investigation of Insulin Resistance and Vitamin E Deficiency in Chronic Inflammatory Demyelinatıng Polyneuropathy: A 5‑year Retrospective Study

Sayfa
24–28
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our study could not reveal any evidence about insulin resistance and Vitamin E deficiency in CIDP patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable disease; therefore, accurate diagnosis and detection of coexisting disorders are very important.
📊
Temel Bulgular & Veri:Results: A statistically significant difference was not found between CIDP and control groups as for the distribution of mean ages, genders, Homeostatic Model Assessment Index values, impaired fasting glucose, and a statistically significant difference was not found between CIDP and control groups as for Vitamin E deficiency.
💡
Sonuç & Katkı:Conclusion: Our study could not reveal any evidence about insulin resistance and Vitamin E deficiency in CIDP patients.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable disease; therefore, accurate diagnosis and detection of coexisting disorders are very important. Some authors have reported that CIDP was more frequently observed in patients with diabetes mellitus when compared with the population in general. Vitamin E deficiency leads to demyelinating neuropathy, and Vitamin E supplementation ensures clinical and electrophysiological recovery. In this study, identifying the association between insulin resistance, Vitamin E deficiency, and CIDP is aimed. Materials and Methods: Thirty‑three patients with CIDP and forty healthy controls were evaluated. Two groups were compared in terms of insulin resistance and Vitamin E level status. Results: A statistically significant difference was not found between CIDP and control groups as for the distribution of mean ages, genders, Homeostatic Model Assessment Index values, impaired fasting glucose, and a statistically significant difference was not found between CIDP and control groups as for Vitamin E deficiency. Conclusion: Our study could not reveal any evidence about insulin resistance and Vitamin E deficiency in CIDP patients.

🔖

Bu Makaleye Atıf Yap

TOZ, H. T., GÖZKE, E. (2020). Investigation of Insulin Resistance and Vitamin E Deficiency in Chronic Inflammatory Demyelinatıng Polyneuropathy: A 5‑year Retrospective Study. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 1, 24–28. https://ajindex.com/articles/290609

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Lewis RA. Chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 2017;30:508‑12
  2. Cornblath DR, Gorson KC, Hughes RA, Merkies IS. Observations on chronic inflammatory demyelinating polyneuropathy: A plea for a rigorous approach to diagnosis and treatment. J Neurol Sci 2013;330:2‑3
  3. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311‑24
  4. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 2006;16:293‑303
  5. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. European Federation of Neurological Societies/ Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:326-2
  6. Rentzos M, Anyfanti C, Kaponi A, Pandis D, Ioannou M, Vassilopoulos D. Chronic inflammatory demyelinating polyneuropathy: A 6‑year retrospective clinical study of a hospital‑based population. J Clin Neurosci 2007;14:229‑35
  7. Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurol 2015;85:498‑504
  8. Chiò A, Plano F, Calvo A, Leone M, Mutani R, Cocito D, et al. Comorbidity between CIDP and diabetes mellitus: Only a matter of chance? Eur J Neurol 2009;16:752‑4
  9. Fatehi F, Nafissi S, Basiri K, Amiri M, Soltanzadeh A. Chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Res Med Sci 2013;18:438‑41
  10. Lotan I, Hellman MA, Steiner I. Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus. Acta Neurol Scand 2015;132:278‑83
  11. Dunnigan SK, Ebadi H, Breiner A, Katzberg HD, Barnett C, Perkins BA, et al. The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes – An observational study. PLoS One 2014;9:e89344
  12. Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurol 2009;73:39‑45
  13. Dunnigan SK, Ebadi H, Breiner A, Katzberg HD, Lovblom LE, Perkins BA, et al. Comparison of diabetes patients with “demyelinating” diabetic sensorimotor polyneuropathy to those diagnosed with CIDP. Brain Behav 2013;3:656‑63
  14. Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropa